San Diego, CA -- (SBWIRE) -- 03/31/2015 -- An investigation on behalf of investors of OHR Pharmaceutical Inc (NASDAQ:OHRP) shares over potential securities laws violations by OHR Pharmaceutical and certain of its directors and officers in connection certain financial statements was announced.

Investors who purchased shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of OHR Pharmaceutical Inc (NASDAQ:OHRP) concerning whether a series of statements by OHR Pharmaceutical regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On March 27, 2015, OHR Pharmaceutical Inc announced the results of a mid-stage study of its lead drug, OHR-102. The study was designed to determine whether the drug could be used in tandem with the existing treatment, injectable eye drug Lucentis, to reduce the number of Lucentis injections patients required. But Ohr announced that there was no "meaningful" reduction in the number of injections required when OHR-102 was used, and that its study had thus failed its primary endpoint.

Shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) declined from $9.97 per share on March 24, 2015, to as low as $2.72 per share on March 27, 2015.

Those who purchased shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com